Home » White Paper: T2Bacteria® Panel Demonstrates Substantial Clinical Impact in Independent, Real World Implementations
White Paper: T2Bacteria® Panel Demonstrates Substantial Clinical Impact in Independent, Real World Implementations
Rapid, direct-from-whole-blood diagnostics that enable improvements in clinical decisions and patient outcomes, while supporting antimicrobial stewardship.
Rapid, direct from whole blood diagnostics are a crucial tool in helping to improve the outcome of patients suffering from bloodstream infections and sepsis, by providing results that help to get them on effective therapy earlier.
Unfortunately, the current standard of care diagnostic methods requires a positive blood culture to provide species identification results and enable appropriate species-directed therapy.
Read our latest white paper that discusses how their technology can enable improvements in clinical decisions and patient outcomes while supporting antimicrobial stewardship. This white paper also discusses findings from the pivotal study on their T2Bacteria Panel, which shows that species identification results were available with T2Bacteria more than 60 hours faster than with blood culture-based methods.
Please fill out the form below for instant access to this white paper!
Sensitivity: 90%7 Specificity: 98%7
E. faecium S. aureus K. pneumoniae A. baumannii P. aeruginosa E. coli
T2 BIOSYSTEMS OVERVIEW
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.